Focus Partners Wealth Has $1.06 Million Stock Position in Liquidia Co. (NASDAQ:LQDA)

Focus Partners Wealth grew its stake in Liquidia Co. (NASDAQ:LQDA - Free Report) by 20.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 90,500 shares of the company's stock after purchasing an additional 15,500 shares during the period. Focus Partners Wealth owned approximately 0.11% of Liquidia worth $1,064,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. D. E. Shaw & Co. Inc. bought a new stake in shares of Liquidia in the 4th quarter valued at approximately $142,000. Deutsche Bank AG grew its stake in shares of Liquidia by 53.4% in the 4th quarter. Deutsche Bank AG now owns 51,075 shares of the company's stock valued at $601,000 after purchasing an additional 17,790 shares during the period. Crestline Management LP grew its stake in shares of Liquidia by 69.8% in the 4th quarter. Crestline Management LP now owns 83,305 shares of the company's stock valued at $980,000 after purchasing an additional 34,246 shares during the period. Cetera Investment Advisers grew its stake in shares of Liquidia by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock valued at $367,000 after purchasing an additional 1,277 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in shares of Liquidia in the 4th quarter valued at approximately $163,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Down 1.3%

NASDAQ:LQDA traded down $0.21 during trading hours on Friday, hitting $15.35. 4,742,122 shares of the stock were exchanged, compared to its average volume of 1,065,159. The company's 50 day moving average is $14.74 and its two-hundred day moving average is $13.57. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $19.41. The company has a market capitalization of $1.31 billion, a P/E ratio of -9.42 and a beta of 0.24.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The firm had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. On average, equities research analysts expect that Liquidia Co. will post -1.51 EPS for the current year.

Analyst Ratings Changes

LQDA has been the topic of several analyst reports. Wall Street Zen upgraded Liquidia from a "sell" rating to a "hold" rating in a research note on Thursday. Oppenheimer set a $13.00 price target on Liquidia and gave the stock an "underperform" rating in a research report on Monday. HC Wainwright restated a "buy" rating and set a $29.00 price target on shares of Liquidia in a research report on Monday, May 12th. Needham & Company LLC restated a "buy" rating and set a $25.00 price target on shares of Liquidia in a research report on Wednesday. Finally, Raymond James increased their price target on Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $25.56.

Insiders Place Their Bets

In other Liquidia news, insider Jason Adair sold 1,856 shares of the company's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the transaction, the insider now owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. This represents a 1.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Roger Jeffs sold 14,130 shares of the company's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the transaction, the chief executive officer now directly owns 1,006,420 shares in the company, valued at approximately $13,657,119.40. This represents a 1.38% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,138 shares of company stock valued at $450,233. 26.50% of the stock is currently owned by corporate insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).